239 related articles for article (PubMed ID: 19689330)
21. Neurochemical brain imaging investigations of schizophrenia.
Soares JC; Innis RB
Biol Psychiatry; 1999 Sep; 46(5):600-15. PubMed ID: 10472414
[TBL] [Abstract][Full Text] [Related]
22. [NMDA-type glutamate receptor and schizophrenia].
Nishikawa T; Ishiwata S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
[TBL] [Abstract][Full Text] [Related]
23. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.
Moghaddam B; Javitt D
Neuropsychopharmacology; 2012 Jan; 37(1):4-15. PubMed ID: 21956446
[TBL] [Abstract][Full Text] [Related]
24. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia.
Holcomb HH; Lahti AC; Medoff DR; Cullen T; Tamminga CA
Neuropsychopharmacology; 2005 Dec; 30(12):2275-82. PubMed ID: 16034443
[TBL] [Abstract][Full Text] [Related]
25. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies.
Marsman A; van den Heuvel MP; Klomp DW; Kahn RS; Luijten PR; Hulshoff Pol HE
Schizophr Bull; 2013 Jan; 39(1):120-9. PubMed ID: 21746807
[TBL] [Abstract][Full Text] [Related]
26. In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: Potential relevance to schizophrenia.
Kim SY; Lee H; Kim HJ; Bang E; Lee SH; Lee DW; Woo DC; Choi CB; Hong KS; Lee C; Choe BY
NMR Biomed; 2011 Dec; 24(10):1235-42. PubMed ID: 21560175
[TBL] [Abstract][Full Text] [Related]
27. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
Gaspar PA; Bustamante ML; Silva H; Aboitiz F
J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
[TBL] [Abstract][Full Text] [Related]
28. Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction.
Kosten L; Verhaeghe J; Verkerk R; Thomae D; De Picker L; Wyffels L; Van Eetveldt A; Dedeurwaerdere S; Stroobants S; Staelens S
Psychiatry Res Neuroimaging; 2016 Feb; 248():1-11. PubMed ID: 26803479
[TBL] [Abstract][Full Text] [Related]
29. Glutamatergic Deficits in Schizophrenia - Biomarkers and Pharmacological Interventions within the Ketamine Model.
Haaf M; Leicht G; Curic S; Mulert C
Curr Pharm Biotechnol; 2018; 19(4):293-307. PubMed ID: 29929462
[TBL] [Abstract][Full Text] [Related]
30. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy: a [(123)I]CNS-1261 SPET study.
Stone JM; Erlandsson K; Arstad E; Squassante L; Teneggi V; Bressan RA; Krystal JH; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2008 Apr; 197(3):401-8. PubMed ID: 18176855
[TBL] [Abstract][Full Text] [Related]
31. [Role of astrocytes in alterations of glutamatergic neurotransmission in schizophrenia].
Kolomeets NS
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(1):110-117. PubMed ID: 25945378
[TBL] [Abstract][Full Text] [Related]
32. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study.
Rowland LM; Bustillo JR; Mullins PG; Jung RE; Lenroot R; Landgraf E; Barrow R; Yeo R; Lauriello J; Brooks WM
Am J Psychiatry; 2005 Feb; 162(2):394-6. PubMed ID: 15677610
[TBL] [Abstract][Full Text] [Related]
33. Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies.
Merritt K; Egerton A; Kempton MJ; Taylor MJ; McGuire PK
JAMA Psychiatry; 2016 Jul; 73(7):665-74. PubMed ID: 27304221
[TBL] [Abstract][Full Text] [Related]
34. Glutamate in dorsolateral prefrontal cortex and auditory verbal hallucinations in patients with schizophrenia: A
Ćurčić-Blake B; Bais L; Sibeijn-Kuiper A; Pijnenborg HM; Knegtering H; Liemburg E; Aleman A
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Aug; 78():132-139. PubMed ID: 28546056
[TBL] [Abstract][Full Text] [Related]
35. Direct and indirect modulation of the N-methyl D-aspartate receptor.
Marino MJ; Conn PJ
Curr Drug Targets CNS Neurol Disord; 2002 Feb; 1(1):1-16. PubMed ID: 12769631
[TBL] [Abstract][Full Text] [Related]
36. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.
Krystal JH; D'Souza DC; Mathalon D; Perry E; Belger A; Hoffman R
Psychopharmacology (Berl); 2003 Sep; 169(3-4):215-33. PubMed ID: 12955285
[TBL] [Abstract][Full Text] [Related]
37. Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signaling.
Noetzel MJ; Jones CK; Conn PJ
Discov Med; 2012 Nov; 14(78):335-43. PubMed ID: 23200065
[TBL] [Abstract][Full Text] [Related]
38. Ketamine modulates hippocampal neurochemistry and functional connectivity: a combined magnetic resonance spectroscopy and resting-state fMRI study in healthy volunteers.
Kraguljac NV; Frölich MA; Tran S; White DM; Nichols N; Barton-McArdle A; Reid MA; Bolding MS; Lahti AC
Mol Psychiatry; 2017 Apr; 22(4):562-569. PubMed ID: 27480494
[TBL] [Abstract][Full Text] [Related]
39. Effect of L-theanine on glutamatergic function in patients with schizophrenia.
Ota M; Wakabayashi C; Sato N; Hori H; Hattori K; Teraishi T; Ozawa H; Okubo T; Kunugi H
Acta Neuropsychiatr; 2015 Oct; 27(5):291-6. PubMed ID: 25896423
[TBL] [Abstract][Full Text] [Related]
40. Central N-acetyl aspartylglutamate deficit: a possible pathogenesis of schizophrenia.
Tsai SJ
Med Sci Monit; 2005 Sep; 11(9):HY39-45. PubMed ID: 16127367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
